 |
AcompliaReport |
Your INDEPENDENT source of news and reviews about the new diet drug Acomplia (rimonabant) |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| Acomplia News from May 2005 -- News About Rimonabant | |
Sanofi-Aventis Hoping to Launch Acomplia Before End of Year |
|
Sanofi-Aventis, developer of the much touted obesity drug Acomplia, told financial analysts on May 13th that it was preparing to launch the drug as early as the end of this year. Hanspeter Spek, the company's executive vice president of pharmaceutical operations, indicated that Sanofi was very close to filing for approval to market the drug with the U.S. Food and Drug Administration and European regulators. "The earliest possible launch date is the end of the fourth quarter," Spek said. Spek and Jean-Claude Leroy were speaking on a conference call to financial analysts after Sanofi-Aventis released a report on its first-quarter earnings.
|
|
We subscribe to the HONcode principles of the HON Foundation. This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Synthelabo Inc., which plans to market it under the trademarked name Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.
(c) 2004-2006 Medical Week News, Inc. All Rights Reserved
Last Updated: 11/08/2005